Mutations in LZTR1 have been identified in patients with RAS/MAPK signaling pathway-dependent congenital malformation syndrome (RASopathies), glioblastoma, and several cancers via activation of the RAS/MAPK signaling pathway [8–16]. Here, LZTR1 is linked to cancer.